XCUR - Exicure, Inc.
| Previous Close | 2.8400 |
| Open | 2.8400 |
| Bid | 1.7500 x 800 |
| Ask | 2.9900 x 800 |
| Day's Range | 2.7898 - 2.9700 |
| 52 Week Range | 1.6200 - 4.1000 |
| Volume | 117,240 |
| Avg. Volume | 321,014 |
| Market Cap | 220M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4260 |
| Earnings Date | Nov 7, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.00 |
- Yahoo Finance Video
Healthcare now advanced through technology
Using your DNA to fight disease, Exicure uses biotechnology and digital drug design to create customized treatments for genetic disorders and other rare diseases. Exicure CEO, Dr. David Giljohann joins the show with more.
- MarketWatch
Exicures shares up on Allergan partnership
Shares of Exicure are up 26% in premarket trading on the news that the biotechnology company entered into an agreement with Allergan to develop treatments for hair loss disorders. Exicure will receive an upfront payment of $25 million. In addition, it can receive milestone payments up to $97.5 million per R&D program and up to $265 million per commercial program. Allergan's portfolio has long been known for top-selling beauty brands like the medical fillers Botox and Juvéderm. Its $63 billion acquisition by AbbVie is expected to close early next year. Exicure stock is down 30.51% year-to-date, while the S&P 500 has risen 23%.
- Business Wire
Exicure and Allergan Enter Into Collaboration, Option and License Agreement to Discover and Develop SNA-based Treatments for Hair Loss Disorders
Exicure, Inc., (XCUR) a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced that Allergan’s wholly-owned subsidiary, Allergan Pharmaceuticals International Limited, and Exicure, Inc. have entered into a global collaboration agreement to discover and develop novel treatments for hair loss disorders based on Exicure’s proprietary SNA technology. Under the terms of the agreement, Allergan will receive exclusive access and options to license SNA-based therapeutics arising from two collaboration programs related to the treatment of hair loss disorders.
- Business Wire
Exicure’s CEO David Giljohann Honored in Crain’s 40 Under 40 Class of 2019
Crain’s “40 Under 40” recognizes individuals who are reinventing what it means to do business in Chicago through financial impact and community leadership. Dr. Giljohann, along with the other honorees, will be profiled in the November 18 issues of Crain’s Chicago Business. “It is truly an honor to be recognized for my work at Exicure, which has always been driven by my personal goal of positively impacting patients by creating revolutionary new medicines,” says Giljohann.
- Business Wire
Exicure Reports Third Quarter 2019 Financial Results and Recent Developments
Exicure, Inc. , a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid technology, today reported financial results for the third quarter ended September 30, 2019 and provided an update on corporate progress.
- Business Wire
Exicure to Present at 2019 BIO Investor Forum
Exicure, Inc. , a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced today that its chief financial officer, David Snyder, will give a company update on Tuesday, October 22, 2019 at 11:00am PT at the 2019 BIO Investor Forum in San Francisco.
- Business Wire
Exicure Presents Positive Biomarker Results from Clinical Trial of XCUR17
Exicure, Inc. (XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced that its chief executive officer, Dr. David Giljohann, presented clinical data from the company’s drug candidate XCUR17 in psoriasis today during the Oligonucleotides Clinical Studies session at the 15th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) in Munich.
- Business Wire
Exicure to Present Clinical Results from XCUR17 at the 15th Annual Meeting of the Oligonucleotide Therapeutics Society
Exicure, Inc. (XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that its CEO, David Giljohann, PhD, will present clinical data from the company’s Phase 1 study of its drug candidate XCUR17 in psoriasis. The presentation, titled “Clinical Results from XCUR17, a Topically Applied Antisense Spherical Nucleic Acid in Patients with Psoriasis,” will take place on Wednesday, October 16, 2019 at the 15th Annual Meeting of the Oligonucleotide Therapeutics Society in Munich. The presentation will occur during Session IX, which is focused on Oligonucleotide Clinical Studies.
- Simply Wall St.
Introducing Exicure (NASDAQ:XCUR), The Stock That Dropped 42% In The Last Year
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. But if...
- Simply Wall St.
Is Exicure (NASDAQ:XCUR) Using Debt Sensibly?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
- Business Wire
Exicure Announces Preclinical Data Supporting Development of SNA Technology in the Central Nervous System
Exicure, Inc. (XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced data from a preclinical study evaluating the biodistribution of SNAs in the non-human primate central nervous system. In Exicure’s foundational study, 7mg of radio-labeled SNAs were injected intrathecally into cynomolgus monkeys. The biodistribution of the SNAs was followed for 14 days by PET/CT scans.
- Business Wire
Exicure to Present at LD Micro 9th Invitational Conference
Exicure, Inc. , the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced today that its CFO, David Snyder, will give a company presentation on Tuesday, June 4th, 2019 at 3:40-4:00 pm MDT at the LD Micro 9th Invitational Conference.
- Business Wire
Exicure to Present at TIDES 2019 on Preclinical and Clinical Development of AST-008
Exicure, Inc. , the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced a presentation at TIDES: Oligonucleotide and Peptide Therapeutics, the world’s largest meeting to accelerate oligonucleotide and peptide products from early discovery to late-stage development and commercialization.
- Business Wire
Exicure to Present Poster at SID 2019 Annual Meeting Demonstrating Bi-Specific Gene Targeting in Dermatology
Exicure, Inc. , the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced a poster presentation at the Society for Investigative Dermatology Meeting, May 8-11, in Chicago.
- Business Wire
Exicure, Inc. Reports First Quarter 2019 Financial Results and Reviews Corporate Progress
Exicure, Inc. , a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, today reported financial results for the first quarter ended March 31, 2019 and provided an update on corporate progress.
- Business Wire
Exicure to Present Poster at AAN 2019
Exicure, Inc. , the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced a poster presentation at the 2019 American Academy of Neurology Annual Meeting in Philadelphia, Pa.
- Business Wire
Exicure to Present Poster at ARVO 2019
Exicure, Inc. , the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced a poster presentation at ARVO 2019 Annual Meeting in Vancouver, British Columbia.
